Skip to main content
KN logo

KN · Knowles Corp

Track KN — free
$32.83 +0.51 (+1.58%)
Market Cap
$2.74B
Shares
84.72M
Volume · Nov 17 319.02K Avg daily vol (3M) 754.47K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$32.32 Open$31.81 Day$31.81–32.66 52W close$20.67–42.80 Avg vol 30d779K Short int3.7M · 4.4% of shares · 4.1d Short vol60% Last earningsOct 22, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 27

Up next

Feb 4, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 10
Current report 8-K
8-10% Revenue CAGR and 10-14% Adjusted EBITDA CAGR

Knowles Corporation’s investor presentation targets 8-10% revenue CAGR and 10-14% adjusted EBITDA CAGR, with 16-20% cash from operations as a % of revenue. The presentation also reports $593M in 2025 revenue.

Regulation FD disclosure
3 source passages
8-10% Revenue CAGR 10-14% Adjusted EBITDA† CAGR 2 0 2 6 - 2 0 2 9 16-20% Cash from Operations as a % of Revenue $593M 2025 Revenue Open the document at this passage
Oct 27
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

Knowles Corporation reported third-quarter 2026 revenue of $184.0 million, up 20.3%, and nine-month revenue of $503.9 million, up 16.9%. Growth reflected higher demand in electrification, industrial, defense and medtech markets and higher pricing.

Revenue $184M ▲ 20.3% Net income $21.6M ▲ 24.1% Diluted EPS $0.25 ▲ 25.0%
Read from the MD&A section
Oct 22
Earnings call
Q3 2026 earnings call

Knowles reported third quarter 2026 revenue of $184 million, up 20% year-over-year, EPS of $0.38 and operating cash flow of $45 million. It guided fourth-quarter 2026 revenue between $180 and $190 million and expected full-year 2026 revenue growth of 16 percent.

Oct 22
Current report 8-K
Financial results

Knowles Corporation reported Q3 2026 revenue of $184 million, up 20% year over year, and full-year 2026 revenue estimated at $689 million. Q4 2026 revenue outlook was $180 to $190 million.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$666.10M
Trailing 12 months
Net income (TTM)
$71.70M
Trailing 12 months
Revenue growth YoY
+20.3%
Year over year
Operating margin
14.6%
Trailing 12 months
P / E (TTM)
40.7
Trailing earnings · reciprocal yield 2.5%
FCF yield
—
TTM · current market cap
Return on invested capital
9.4%
Trailing 12 months
Net cash
−$69.40M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.5%
Year over year · more shares
Price change (1Y)
+49.3%
Trailing year
Short interest
4.4%
Latest settlement · 4.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 22, 2026
Q3 FY26

TL;DR. Q3 revenue grew 20% to $184 million, non-GAAP EPS increased 15% to $0.38 and operating cash flow was $45 million; Q4 revenue is guided to $180–$190 million, full-year revenue is estimated at $689 million, Precision Devices grew 33%, and management expects its 2027 revenue and adjusted EBITDA growth targets to be exceeded. Offsets include a 210-basis-point decline in MedTech and Specialty Audio adjusted EBITDA margin, capacity constraints, a 2%–3% stamping headwind, higher planned capital spending and operating expenses, and disclosed tariff, material-cost, inventory, inflation and customer-concentration risks.

Bullish
  • + Q3 revenue increased 20% to $184 million and exceeded the high end of guidance, while non-GAAP EPS increased 15% to $0.38 and operating cash flow was $45 million.
  • + Management expects Knowles to continue exceeding its 2027 revenue and adjusted EBITDA growth targets.
  • + Precision Devices revenue grew 33% to $117 million, with a Q3 book-to-bill ratio of 1.5.
  • + Knowles repurchased $25 million of shares and reduced outstanding bank borrowings by $15 million while funding organic growth.
Bearish
  • − Capacity constraints are expected to limit Precision Devices to roughly flat sequential growth despite strong year-over-year growth.
  • − Capital spending is expected to increase from the historic range of 3%–5% of revenue to 5%–7% in 2027.
  • − The exit of the stamping business is expected to create a 2%–3% MedTech and Specialty Audio revenue headwind in 2027, weighted toward the first half.
  • − R&D expense rose $1 million and SG&A expense rose $4 million year over year in Q3.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol High
Market backdrop VIX 22.9 · elevated Equity put/call 0.73
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −3%
below
Price vs 50-day avg −8%
below
RSI (14) 44
neutral
MACD trend Positive
52-week position 53%
mid-range
Momentum
relative strength
Weak
1-month return −7%
trailing
6-month return −14%
trailing
YTD return +51%
this year
Relative strength −13%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $35 › 200d $33 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +42 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.36% of shares out · ▼ -14.2% MoM · 4.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
339 holders — near 3-yr high, broad support
Squeeze score 50
elevated · 0–100
Fundamentals
Strong
Revenue growth +7%
Y/Y
Gross margin 43%
expanding
EPS growth +119%
Y/Y
Valuation P/E 39.9
rich
Buyback $81.5M
remaining
Balance sheet $59.8M
net debt
Quant / Vol
risk profile
High
Volatility 43%
annualized · 1-yr
Max drawdown −29%
past year
ATR 5.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 7 of last 8
Latest guidance · from the 8-K filed Oct 22, 2026
2026 Full year
Revenue $689M
prior FY $593.2M midpoint +16.1% Y/Y
quarter ending December 31, 2026
Diluted earnings per share from continuing operations $0.31 – $0.35
prior qtr $0.25 midpoint +32.0% QoQ
Diluted earnings per share from continuing operations $0.39 – $0.43
Net cash provided by operating activities $60M – $70M
Net cash provided by operating activities $60M – $70M
Q4 2026
Revenues from continuing operations $180M – $190M
prior qtr $184M midpoint +0.5% QoQ
Revenues from continuing operations $180M – $190M
Previous outlook earlier release · from the Earnings Call filed Jul 23, 2026

Still-open targets the latest release did not restate under the same label.

CapEx as % of revenue · 2027 5%
Prior guidance period ended · from the Earnings Call filed Jul 23, 2026
Revenue · Q3 2026 $167M – $177M
Guided vs delivered · last 8 settled
Revenue Q3 2026
guided $167M – $177M
$184M Beat +7.0%
Diluted earnings per share from continuing operations quarter ending September 30, 2026
guided $0.22 – $0.26
$0.25 In line
Revenues from continuing operations the quarter ending June 30, 2026
guided $152M – $162M
$166.8M Beat +6.2%
Diluted earnings per share from continuing operations the quarter ending June 30, 2026
guided $0.18 – $0.22
$0.22 In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−3% Neutral
Price vs 50-day avg
−8% Bearish
RSI (14)
44 Neutral
MACD trend
Positive Bullish
52-week position
53% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $35 › 200d $33 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +42 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.36% of shares out · ▼ -14.2% MoM · 4.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
339 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $21 Now $32 · 53% Range high $43
vs 200-day avg -3% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted earnings before interest, income taxes, depreciation, and amortization ("Adjusted EBITD non-GAAP 32.2M Quarter Ended September 30, 2026 —
Adjusted EBITDA as a % of revenues non-GAAP 24.9% Nine Months Ended September 30, 2026 —
Adjusted free cash flow non-GAAP 62.4M Nine Months Ended September 30, 2026 —
Adjusted free cash flow as a % of revenues non-GAAP 12.4% Nine Months Ended September 30, 2026 —
Net Cash from Operations $45M Q3 2026 —
Net debt leverage ratio 0.4 September 30, 2026 —
Non-GAAP capital expenditures attributable to continuing operations non-GAAP -24.6M Nine Months Ended September 30, 2026 —
Non-GAAP net cash attributable to continuing operations non-GAAP 87M Nine Months Ended September 30, 2026 —
Non-GAAP operating expenses non-GAAP 117.6M Nine Months Ended September 30, 2026 —
Non-GAAP research and development expenses non-GAAP 28.9M Nine Months Ended September 30, 2026 —
Non-GAAP selling and administrative expenses non-GAAP 88.7M Nine Months Ended September 30, 2026 —
Trailing 12 Month Adjusted EBITDA non-GAAP 166.7M September 30, 2026 —
EBIT margin 14.6% the second quarter of 2026 filing —
MedTech & Specialty Audio Adjusted earnings from continuing operations before interest and incom non-GAAP $27.6M second quarter of 2026 filing —
MedTech & Specialty Audio Adjusted EBIT margin non-GAAP 40.3% second quarter of 2026 filing —
MedTech & Specialty Audio EBIT margin 38.4% second quarter of 2026 filing —
Non-GAAP effective tax rate from continuing operations non-GAAP 16.9% Three Months Ended June 30, 2026 filing —
Precision Devices Adjusted earnings from continuing operations before interest and income taxes non-GAAP $20.3M second quarter of 2026 filing —
Precision Devices Adjusted EBIT margin non-GAAP 20.7% second quarter of 2026 filing —
Precision Devices EBIT margin 14.1% second quarter of 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Electronic Components — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KN
Knowles Corp
this stock
$2.74B +50.8% +7.2% 39.9 4.4%
APH
Amphenol Corp
$186.26B — +51.7% 32.9 1.1%
GLW
Corning Inc
$91.45B +21.3% +19.1% 43.2 1.9%
TEL
TE Connectivity plc
$61.20B -6.2% +15.2% 19.3 2.0%
MRAAF
Murata Manufacturing Co., Ltd.
$54.79B +34.8% — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
339
% held
103.5%
Net QoQ
+683.9K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
355
View
Short & Settlement
Short Interest Falling
Shares short
3.7M
Days to cover
4.1d
Change
-609.5K sh
View
Short Volume
Short vol %
60%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
267
Value
$8.6K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
36.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$593.2M
Net income (FY)
$44.2M
EPS diluted
$0.50
View
Buybacks
Authorized
$400.0M
Remaining
$81.5M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 10, 2026
This year
15

Knowles Corporation’s investor presentation targets 8-10% revenue CAGR and 10-14% adjusted EBITDA CAGR, with 16-20% cash from operations as a % of revenue. The presentation also reports $593M in 2025 revenue.

View
Proposed Sales
Value
$259.9K
Shares
6.6K
Filed
Aug 17, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 22, 2026
View
Investor Relations
Latest news
Knowles Reports Q3 2026 Financial…
Published
Oct 22, 2026
View

Performance

5D 20D 120D MTD YTD
KN -2.2% -6.7% -14.1% -1.7% +50.8%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -0.5% -3.2% -12.7% +0.4% +42.3%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$400.00M
Spent (derived)
$318.50M
Remaining
$81.50M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1587523 CUSIP 49926D109 13F (30d) 333 filings 310 filers Visit website Investor relations